Ophthalmic

FTC Proposes Updating Eyeglass Rule to Require Prescribers to Get Signed Confirmation When Providing a Prescription to Their Patients

Retrieved on: 
Friday, December 16, 2022
Consumer, Social media, Lens (anatomy), Contact lens, Consumer protection, Ophthalmic, Contact, Federal Register, Blog, Glasses, Patient, Federal Trade Commission, FTC, Prescription, Commission, News, Ophthalmology, Processor register, California Naloxone Requirement Bill, Insurance, Bureau, Health insurance, Pharmaceutical industry, Dietary supplement

To remedy that and enforce the law we are proposing that prescribers now get a signed confirmation when they release prescriptions to their patients.

Key Points: 
  • To remedy that and enforce the law we are proposing that prescribers now get a signed confirmation when they release prescriptions to their patients.
  • Under the rule, prescribers also cannot require that patients buy eyeglasses as a condition of providing them with a copy of their prescription, place a liability waiver on the prescription, require patients to sign a waiver, or require patients to pay an additional fee in exchange for a copy of their prescription.
  • Prescribers further cannot refuse to perform an eye exam unless the patient buys eyeglasses, contact lenses, or other ophthalmic goods from them.
  • Follow the FTC on social media, read consumer alerts and the business blog, and sign up to get the latest FTC news and alerts.

Ophthalmic Images Now Available through the Academy IRIS® Registry, Curated at Scale by Verana Health's VeraQ Engine

Retrieved on: 
Thursday, September 29, 2022
People, American Academy, Center, Master of Science, Medicare, Research, IRIS, Patient, GA, Physician, Technology, Spectrum disorder, American Urological Association, Disease, Geographic atrophy, RWD, Organization, CMS, OCT, Multiple sclerosis, Doctor of Philosophy, HCPS, SAN, Associate, Associated Students of the University of Washington, Medicine, Health, Comparison, VTC, Registry, CATT, Population, Data management, MIPS, MIGS, American Academy of Neurology, 2021 Essex County Council election, Data, Clinical trial, E350, Artificial intelligence, Poster, Macular degeneration, Ophthalmic, EHR, AAO, Millennium, Academy, Machine learning, Biomarker, Bergen County Academies, Deep learning, Quality of life, Solution, HCP, Diagnosis, DEX, AMD, University, Medical imaging, Medical device, Pharmaceutical industry, MD, Ophthalmology

SAN FRANCISCO , Sept. 29, 2022 /PRNewswire/ -- Verana Health® announced today the introduction of ophthalmic images into its VeraQ™ population health data engine. The ~3.5 million images—spanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and more—are being incorporated into the Academy IRIS® Registry. This data is managed by Verana Health via VeraQ, where it is linked with de-identified electronic health record (EHR) data and curated with clinician oversight and artificial intelligence (AI), such as machine learning (ML), to produce quality data variables and Ophthalmology Qdata™ modules. These image-derived variables and Qdata modules—being introduced to the ophthalmic community at the Academy's Annual Meeting (AAO 2022)—will be selectively available in the future to academic research institutions participating in the IRIS Registry Analytic Center Consortium and life sciences organizations, respectively.

Key Points: 
  • American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) extends data footprint by making available data from more than 3.5 million images of eyes.
  • SAN FRANCISCO, Sept. 29, 2022 /PRNewswire/ -- Verana Health announced today the introduction of ophthalmic images into its VeraQ population health data engine.
  • The ~3.5 million imagesspanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and moreare being incorporated into the Academy IRIS Registry.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, quality data modules, Qdata.

Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

Retrieved on: 
Thursday, September 8, 2022
Ophthalmic, IND, Therapy, Retinitis pigmentosa, Entrepreneurship, MCO, Retina, Geographic atrophy, RP, FDA, AMD, Patient, Pharmaceutical industry, Medical device, Review, Stargardt disease, Atomic de Broglie microscope

DALLAS, Sept. 8, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope's Multi-Characteristic Opsin (MCO) gene therapy platform and participate in a panel titled " Gene Therapy for Ophthalmic Disorders A Year in Review " at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting , taking place September 13-16, 2022 in Boston, MA.

Key Points: 
  • DALLAS, Sept. 8, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope's Multi-Characteristic Opsin (MCO) gene therapy platform and participate in a panel titled " Gene Therapy for Ophthalmic Disorders A Year in Review " at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting , taking place September 13-16, 2022 in Boston, MA.
  • Details for the presentation are as follows:
    In addition to highlighting the benefits of MCO gene therapy, Dr. Mohanty will detail Nanoscope's Phase 2b RESTORE trial from its lead clinical program.
  • RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023.
  • Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Ophthalmic Lasers Global Market Report 2022: Advances in Refractive Surgery Enables Vision Optimization for Broader Range of Patients - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Optical, Health, Surgery, Medical Devices, COVID-19, Ophthalmic, Laser, Laser ablation, Excimer, CAGR, YAG laser, Growth, Pet

The "Ophthalmic Lasers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ophthalmic Lasers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Femtosecond Lasers, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$632 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $343 Million, While China is Forecast to Grow at 7.3% CAGR
    The Ophthalmic Lasers market in the U.S. is estimated at US$343 Million in the year 2020.
  • In the global Nd:YAG Lasers segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment.

Dr. Nancy Holekamp of the Pepose Vision Institute joins Vial as an Advisor to their Ophthalmology CRO

Retrieved on: 
Tuesday, July 5, 2022
Medical degree, Disease, Visual Science, Research, Ophthalmic, Retina, SAB, Volkmann's contracture, CRO, SAN, Traction, CTMS, Technology, George Washington University School of Medicine & Health Sciences, Vial, Gastroenterology, Washington University School of Law, Pi, Multimedia, Diabetic retinopathy, Fine chemical, Ophthalmology, Dermatology

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- Vial , a next-generation CRO, site network and technology platform, recently announced the planned launch of an Ophthalmology CRO .

Key Points: 
  • SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- Vial , a next-generation CRO, site network and technology platform, recently announced the planned launch of an Ophthalmology CRO .
  • Vial is pleased to announce that Dr. Nancy Holekamp of the Pepose Vision Institute was brought on as an advisor.
  • Dr. Holekamp currently serves as the Director of Retina Services at the Pepose Vision Institute in St. Louis, MO.
  • Vial has executed on that vision by launching a next-generation CRO (live in Dermatology CRO , with slated launches in Ophthalmology CRO , Oncology CRO , Gastroenterology CRO ), a site network ( Dermatology Clinical Trials , Ophthalmology Clinical Trials , Gastroenterology Clinical Trials , Women's Health Clinical Trials , Neurology Clinical Trials ), and technology platform ( VialConnect CTMS ) to accelerate research.

Nationally Recognized Ophthalmologist Ehsan Sadri, M.D. FACS and Industry Veteran Tom Mitro Appointed to Visiox's Board of Directors

Retrieved on: 
Tuesday, June 7, 2022
Allergan, Board of directors, Aerie, Aerie Pharmaceuticals, COO, Ophthalmology, LinkedIn, CEO, Glaucoma, Inflammation, Ophthalmic, Founder, Ecosystem, IOP, ISTA Pharmaceuticals, Technology, Board, Native American Venture Fund, Cataract surgery, FACS, TJM, Pharmaceutical industry, Management

TARRYTOWN, N.Y., June 7, 2022 /PRNewswire/ -- Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that it has appointed two new executives, Ehsan Sadri, M.D. FACS and Tom Mitro to its Board of Directors.

Key Points: 
  • FACS and Tom Mitro to its Board of Directors.
  • "We are very pleased to have Dr. Sadri and Mr. Mitro join our Board of Directors," said Michael Derby, Visiox's Founding Investor and Executive Chairman.
  • Tom Mitro brings over 3 decades of experience with his most recent position as President and COO of Aerie Pharmaceuticals, an ophthalmology focused pharmaceutical company.
  • "On behalf of the entire board of directors and executive team, we welcome Dr. Sadri and Mr. Mitro," said Ryan S. Bleeks, CEO.

The Worldwide Ophthalmic Packaging Industry is Expected to Reach $8.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022
Packaging, Optical, Health, Manufacturing, Ophthalmic, Use, R, Certification, Customer support, Compound annual growth rate, Investment, Business Growth Fund, Strategic management, USD, Decision-making, COVID-19, Market share analysis, CAGR, Acquisition, Growth, Value, Retail, Medical device

What are the inhibiting factors and impact of COVID-19 shaping the Global Ophthalmic Packaging Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Ophthalmic Packaging Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ophthalmic Packaging Market?
  • What is the market share of the leading vendors in the Global Ophthalmic Packaging Market?
  • What modes and strategic moves are considered suitable for entering the Global Ophthalmic Packaging Market?

Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth

Retrieved on: 
Wednesday, May 11, 2022
Board, Dermatology, Financial management, DNA-binding protein, Senior, NASDAQ, GLOBE, Company, Sun, Merck, Physician, Research, Â, Patient, Fibrosis, Acquisition, Inflammation, Therapy, Leadership, Ophthalmology, Tissue, Corporation, Marketing, Alcon, Ophthalmic, Inspiration, Technology, Director, Executive, Granulation tissue, Social media, General manager, Fine chemical, Management, Dermatologic and Ophthalmic Drugs Advisory Committee, Finance, House of Santen

CHARLESTON, S.C. and FORT WORTH, Texas, May 11, 2022 (GLOBE NEWSWIRE) -- Xequel Bio, Inc. (formerly FirstString Research, Inc.), a clinical stage biopharmaceutical company developing dermatologic and ophthalmic therapeutics utilizing its patented new chemical entity aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide), announced today the appointments of Jerry St. Peter as Chief Executive Officer and Wes Brazell as Chief Financial Officer.

Key Points: 
  • Both Jerry and Wes bring extensive corporate leadership, business development execution and entrepreneurial acumen to Xequel.
  • It is a pleasure to join Xequel at such a pivotal moment in its evolution, said Jerry St. Peter, Chief Executive Officer and Board Member.
  • We have also created a strong corporate identity under the Xequel Bio name, reflecting our strategic move into the Companys next chapter.
  • The Company is in the process of developing a new corporate website and updated social media accounts reflecting the Xequel Bio name.

Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, March 28, 2022
Pupil, CRL, Ophthalmic, Pilocarpine, NASDAQ, Therapy, NEW, Marketing, Forward-looking statement, Compliance, Mydriasis, Research, Lens (anatomy), Ernest, MAP, Endpoint security, Visual acuity, Technology, Phenylephrine, Presbyopia, Time, COVID-19, U.S. Securities and Exchange Commission, US, Myopia, GLOBE, NDA, Microcline, Electronics, Eye, FDA, Efficiency, Reflex, Mobile phone, Pharmaceutical industry, Medical device, Lithium, Online gambling, Telescopic sight, Company, Diagnosis

NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial results for the fourth quarter ended December 31, 2021.

Key Points: 
  • For the fourth quarter of 2021, net income was approximately $3.0 million, or $0.11 per share ($0.10 per share on a diluted basis), compared to a net loss of approximately $(4.2) million, or $(0.17) per share, fourth quarter of 2020.
  • Research and development expenses totaled approximately $3.2 million for the fourth quarter of 2021 as compared to $3.4 million for the fourth quarter of 2020.
  • For the fourth quarter of 2021, general and administrative expenses were approximately $3.7 million, compared to $2.0 million for the fourth quarter of 2020.
  • Total operating expenses for the fourth quarter of 2021 were approximately $6.9 million compared to $5.4 million for the comparable period in 2020.

Compulink Partners with Promptly to Provide Cutting-edge Patient Engagement

Retrieved on: 
Thursday, March 24, 2022
Health, Data Management, Practice Management, Technology, Software, Ophthalmic, Organization, University, Automation, No, ASC, Private practice, Practice management software, MIPS, 3D ultrasound, Q&A, CEO, Health, Documentation, Database, EHR, Workflow, Practice management, Solution, Software architect, Patient, Partnership, Hospital, Medicine, Health insurance, COMPULINK HEALTHCARE SOLUTIONS, PROMPTLY LLC

Compulink Healthcare Solutions , a leader in specialty-specific all-in-one EHR solutions, has announced its partnership with Promptly, provider of the leading comprehensive web-based patient experience suite on the market, to deliver new mobile-friendly patient engagement tools for its Advantage SMART Practice solution.

Key Points: 
  • Compulink Healthcare Solutions , a leader in specialty-specific all-in-one EHR solutions, has announced its partnership with Promptly, provider of the leading comprehensive web-based patient experience suite on the market, to deliver new mobile-friendly patient engagement tools for its Advantage SMART Practice solution.
  • Patient kiosk accessible from mobile phone or in-office tablet for easy update of patient information, scanning of drivers license/insurance card, e-sign of consents, and frictionless payment.
  • Patient cost estimator using real-time data to provide patients with price transparency and accelerate collections while satisfying the No Surprises Act.
  • Promptly is a comprehensive web-based patient experience and automation suite designed for medical practices to enhance patient touchpoints, accelerate patient payments and automate processes to support your team while combating staffing shortages.